PD-L1/HDAC3-IN-1
PD-L1/HDAC3-IN-1 (PH3) is a dual PD-L1/HDAC3 Inhibitor with IC50 values of 89.4 nM and 107 nM for PD-1/PD-L1 and HDAC3, respectively. PD-L1/HDAC3-IN-1 induces cell apoptosis and arrests cell cycle at G0/G1 phase. PD-L1/HDAC3-IN-1 shows anticancer activity both in vivo and in vitro[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; HDAC; PD-1/PD-L1
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation
Field of Research
Cancer
Smiles
CC1=C(C=CC=C1C2=CC=CC=C2)C3=NC(OC)=C(C=C3)CNCCCC(NNCCC)=O
Molecular Formula
C27H34N4O2
Molecular Weight
446.58
References & Citations
[1]Wang Z, et al. Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy. J Med Chem. 2025 Apr 24;68 (8) :8046-8064.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400096-100 1x 100 µL
Histone H1 (AE-4), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400630-100 1x 100 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472059-500 1x 500 µL
TNFS15 / VEGI (Vascular Endothelial Growth Inhibitor) (rVEGI/1283), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740952-500 1x 500 µL
Human IgG Immunoglobulin (B33/20), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400902-100 1x 100 µL
Nucleolin (NCL/902), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details